DexCom Inc (DXCM)vsSpectral AI Inc. (MDAI)
DXCM
DexCom Inc
$83.03
-1.75%
HEALTHCARE · Cap: $31.90B
MDAI
Spectral AI Inc.
$1.60
+2.56%
HEALTHCARE · Cap: $50.21M
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 32182% more annual revenue ($4.97B vs $15.39M). DXCM leads profitability with a 20.1% profit margin vs -65.5%. DXCM earns a higher WallStSmart Score of 74/100 (B).
DXCM
Strong Buy74
out of 100
Grade: B
MDAI
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DXCM.
Margin of Safety
-18.5%
Fair Value
$1.30
Current Price
$1.60
$0.30 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Trading at 11.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -2308.0% — below average capital efficiency
Revenue declined 30.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : MDAI
The strongest argument for MDAI centers on Debt/Equity.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : MDAI
The primary concerns for MDAI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
DXCM profiles as a mature stock while MDAI is a turnaround play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.42 — expect wider price swings.
DXCM is growing revenue faster at 13.1% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 17/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Spectral AI Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Spectral MD Holdings, Ltd., a predictive analytics company, develops AI algorithms and optical technology in wound care treatment. The company is headquartered in Dallas, Texas.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?